Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
RA’ANANA, Israel, May 11, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Company has been selected for an oral podium presentation and a poster presentation at the upcoming American Urology Association 2017 Annual Meeting in Boston, Massachusetts from May 12 to May 16, 2017.
The oral podium and poster presentations are related to UroGen Pharma’s clinical stage uro-oncology product candidates, as detailed below:
Oral podium presentation: PD19-10: The Chemoablative Effect of VesiGel Instillation in Patients with NMIBC – Response Rate and One-Year Durability
Presenting Author: Andrew Lenis, MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
Session: Bladder Cancer: Non-Invasive II on Saturday, May 13 from 8:30 am EDT to 8:40 am EDT
Poster presentation based on abstract title: MP98-05: Checkpoint Inhibition with Systemic Anti-Programmed Cell Death Ligand-1 and Intravesical TMX-101 (Vesimune) Decrease Tumor Burden in a Mouse Model of Urothelial Carcinoma
Presenting Author: Andrew T. Lenis MD MS, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California
Session: Bladder Cancer: Basic Research & Pathophysiology on Tuesday, May 16 from 9:30 am EDT to 11:30 am EDT
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
CONTACT: Gary Titus, UroGen Pharma Ltd. 689 Fifth Avenue, 14th Floor New York, NY 10022 [email protected] 646-768-9531 Stephanie Carrington, ICR, Inc. 685 Third Avenue, 2nd Floor New York, NY 10017 [email protected] 646-277-1282
